21 January 2015
S&P BSE Sensex
S&P BSE Sensex: Daily
S&P BSE-100
30000
28000
26000
24000
22000
20000
18000
42.91
522.67
.
8,771.82
28,784.67
.
2 S&P BSE-200
Nifty
3,588.23
Sensex P/ E : 19.50
Total
1552
1419
120
3091
21/01/2015
0.26
0.36
0.61
20/01/2015
0.26
0.35
0.61
61.63
71.57
52.23
93.27
Euro
JPY
GBP
Indicators
Inflation Rate (CPI)
Interbank Call
91-day T-Bills
61.76
71.33
52.68
93.41
19-Jan
3488
3192
29.17
16-Jan
4136
3416
29.74
15-Jan
4306
3384
31.87
14-Jan
3206
2572
28.07
The International Monetary Fund (IMF) has slightly cut projections for India's
economic growth to 6.3% for 2015-16 against 6.4% made in October last year, while
retaining the forecast for the current financial year at 5.6%. In its World Economic
Outlook Update, IMF pegged the country's growth rate at 6.5% for 2016-17.

According to global credit rating firm S&P, the size of global bonds issued by Indian
companies could almost double to $ 25 billion within a few years from $ 14 billion in
2014, with a majority of them likely to take place after 2015.
 World13/08/2012
Bank said that
it will commit
USD 1 billion
in the government's
Bharat 03/
17/08/2012
10/08/2012
09/08/2012
08/08/2012
07/08/2012Swachh
06/08/2012
(Clean India)
7.30 campaign.7.34
7.10
7.09
7.05
7.14
6.85
7.35 (TCS) has
6.69signed a multi-year
6.66
6.54with Virgin6.71
 Tata Consultancy
Services
contract
Atlantic
6.82 cloud, Infrastructure-as-a-Service
5.98
5.94
5.88 and IT 6.01
Airways 6.12
covering private
(IaaS)
support
services. TCS will provide fully managed services to transform and optimise Virgin
Atlantic Airways' IT processes, applications and infrastructure.

Crompton Greaves has bagged a deal with PT PLN (Perusahaan Listrik Negara)
Indonesia, for the manufacture and supply of 37 units of power transformers. Valued at
USD 26 million (about Rs 156 crore), the power transformers will be installed across
PT PLN's transmission network, in 36 different substations in Sumatra, Java, Bali,
Kalimantan and the Sulawesi islands of Indonesia

Suven Life Sciences has received one product patent from Australia, two product
patents from Japan and one product patent from Hong Kong. The patents correspond
to a new chemical entity (NCE) for treatment of disorders associated with
neurodegenerative diseases. These patents are valid through 2030.

Aurobindo Pharma is recalling 24,816 bottles of Gabapentin capsules used as
Forex Rates (Direct quote in INR)
Current Previous
+/USD
Trades
(lac)
32.10

Forward Premia on USD/INR
20/01/2015
7.82
7.32
6.82
Shares
(lac)
3796
(2 Jan 14 –20 Jan 15)
Source: BSE
21/01/2015
7.84
3 Months
7.33
6 Months
6.84
1 Year
LIBOR (USD)
20-Jan
Turnover
(Rs. cr)
3295
Date
8,695.60
Advance Decline Ratio
A
B Others
Advances
172 1094 286
Declines
125 1023 271
Unchanged 3
68
49
Total
300 2185 606
3 Months
6 Months
1 Year
28,784.67
144.90
45.73
TURNOVER BSE
-0.13
0.24
-0.45
-0.14
5.00%
8.05 / 8.10%
8.40%
4.38%anticonvulsant and analgesic following complaints of empty capsules in the US market.
8.45 / Each
8.50%bottle contains 100 capsules of 300 mg.
8.35 %
Brent Crude ($/ Bbl)
7.72%
48.24 (-0.50)
7.93%Inc for marketing HIV drugs. Under the agreement, Gilead has extended non-exclusive
59.38 rights
(-1.86)to Strides to manufacture and distribute Tenofovir Alafenamide (TAF) - used for
Gold Std (Rs./10gm)
28,087 (392)
of-397
AIDS.
26,790treatment
(-164)
36,535
(-200)
 Reliance
Communications’ group entity Telecom Infrastructure Finance Pvt Ltd
10-yr G-Sec
Silver (Rs/ Kg)
World Stock Markets
New York– Dow Jones
NASDAQ
London – FTSE
Hong Kong–Hang Seng
At 9.00 am- Today
Tokyo – Nikkei
At 9.00 am today
1
39,570 (694)

(TIFPL) has paid it Rs 650 crore, increasing promoters’ holding to 59.7% in the
company.
Close
17515
4655
6620
23951
24248
17366
17288
4
20
35
213
297
352
-78
Strides Arcolab Limited has entered into a licensing agreement with Gilead Sciences,

Equity Market Roundup: Sensex opened at 28,325. It made an intra-day high of
28,829 and a low of 28,325 before closing 523 points up at 28,785.

Debt Market Roundup: RBI infused Rs 208.58 bn through the Repo window, while Rs
13.85 bn was absorbed under the reverse repo window.
Disclaimer: This communication is being sent by the Investment Advisory Group of HDFC Bank Ltd., registered under SEBI (Investment Advisors) Regulations,
2013
This note has been prepared exclusively for the benefit and internal use of the recipient and does not carry any right of reproduction or disclosure. Neither this
note nor any of its contents maybe used for any other purpose without the prior written consent of HDFC Bank Ltd, Investment Advisory Group. In preparing this
note, we have relied upon and assumed, without any independent verification, accuracy and completeness of all information available in public domain or from
sources considered reliable.
This note contains certain assumptions and views, which HDFC Bank Ltd, Investment Advisory Group considers reasonable at this point in time, and which are
subject to change. Computations adopted in this note are indicative and are based on current market prices and general market sentiment. No representation or
warranty is given by HDFC Bank Ltd, Investment Advisory Group as to the achievement or reasonableness or completeness of any idea and/or assumptions.
This note does not purport to contain all the information that the recipient may require. Recipients should not construe any of the contents herein as advice
relating to business, financial, legal, taxation, or other matters and they are advised to consult their own business, financial, legal, taxation and other experts /
advisors concerning the company regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this note
and should understand that statements regarding future prospects may not be realized. It may be noted that investments in equity and equity-related securities
involve a degree of risk and investors should not invest any funds unless they can afford to take the risk of losing their investment. Investors are advised to
undertake necessary due diligence before making an investment decision. For making an investment decision, investors must rely on their own examination of
the Company including the risks involved. Investors should note that income from investment in such securities, if any, may fluctuate and that each security’s
price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Neither HDFC Bank nor any of its employees shall be liable
for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way from the information contained
in this material.
This note does not constitute an offer for sale, or an invitation to subscribe for, or purchase equity shares or other assets or securities of the company and the
information contained herein shall not form the basis of any contract. It is also not meant to be or to constitute any offer for any transaction.
HDFC Bank and its affiliates, officers, directors, key managerial persons and employees, including persons involved in the preparation or issuance of this
material may from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein. HDFC Bank may at
any time solicit or provide commercial banking, credit, advisory or other services to the issuer of any security referred to herein. Accordingly, information may be
available to HDFC Bank, which is not reflected in this material, and HDFC Bank may have acted upon or used the information prior to, or immediately following
its publication.
Disclosures:
Research analyst or his/her relatives or HDFC Bank or its associates may have financial interest in the subject company in ordinary course of business.
Research analyst or his/her relatives does not have actual/ beneficial ownership of 1% or more securities of the subject company at the end of the month
immediately preceding the date of publication of research report: HDFC Bank or its associates may have actual/beneficial ownership of 1% or more securities of
the subject company at the end of the month immediately preceding the date of publication of research report. Subject company may have been client of HDFC
Bank or its associates during twelve months preceding the date of publication of the research report. HDFC Bank or its associates may have received
compensation from the subject company in the past twelve months. HDFC Bank or its associates may have managed or co-managed public offering of
securities for the subject company in the past twelve months. HDFC Bank or its associates may havereceived compensation for investment banking or merchant
banking or brokerage services from the subject company in the past twelve months. HDFC Bank or its associates may have received compensation for products
or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months. HDFC Bank or its
associates has not received compensation or other benefits from the subject company or third party in connection with the research report. Research analyst
has not served as an officer, director or employee of the subject company. Neither research analyst nor HDFC Bank has been engaged in market making
activity for the subject company. Three year price history of the daily closing price of the securities covered in this note is available at www.nseindia.com and
www.bseindia.com.
2